Aqara Expands to Amazon UK
28.7.2021 11:00:00 EEST | Business Wire | Press release
Aqara, a provider for smart home products, announced the launch of its first Amazon store in Europe, the Aqara Amazon UK store. Starting from July 28, 2021, a comprehensive suite of Aqara products will be made available on Amazon UK to residents not only in the UK, but also in dozens of European countries that are covered in the Amazon network.
Aqara has been selling smart home products in Europe since 2020 via dozens of authorized distributors, and has become one of the most popular brands among the European smart home community for the high product quality, the accessible prices and the seamless integration with major ecosystems including Apple HomeKit, Amazon Alexa, Google Assistant, and more.
The launch of Aqara’s first Amazon Europe store marks another milestone for the fast-growing brand, offering millions of European consumers an easy and convenient access to the Aqara product lineup. Following its UK Amazon store, Aqara is expected to add two more brand stores on Amazon France and Amazon Germany in the following months.
The product lineup on the Aqara Amazon UK store include:
Aqara Hub M2 (£54.99*) - Aqara’s most advanced and future-proof smart home hub that connects all Aqara devices and allows seamless integration across Aqara sensors and home automation devices;
Aqara Camera Hub G2H (£64.99) - An indoor HomeKit Secure Video camera for home security, with the Zigbee hub function to enhance home security and smart home automations;
Aqara Door & Window Sensor (£17.99) - It detects if a window or a door is open in real time, and enables push notifications or/and local alarm activation when the door/ window opens unexpectedly;
Aqara Temperature & Humidity Sensor (£19.99) - It monitors temperature, humidity, and atmospheric pressure in real time, and can connect with other Aqara devices for home automations and scenes;
Aqara Motion Sensor (£21.99) - It detects human movements with passive infrared and can work with other Aqara products to set home automations and scenes, such as turning on/off lights when it detects activity or inactivity;
Aqara Water Leak Sensor (£19.99) - It detects flood, and enables push notifications or/and local alarm activation to protect the property;
Aqara Vibration Sensor (£19.99) - It detects vibration, tilt and drop, alerts users when unexpected movement is detected, and can be used for home automations and scenes;
Aqara Wireless Switch H1 (£26.99) - A remote switch with 7 configurable actions to control smart home devices or home scenes;
Aqara Wireless Mini Switch (£17.99) - A versatile and compact switch with 3 configurable actions to control smart home devices or home scenes;
Aqara Cube (£19.99) - A versatile controlling cube that recognizes 6 gestures (push, shake, rotate, tap twice, flip 90°, and flip 180°) for smart home control;
Aqara TVOC Air Quality Monitor** (£39.99) - It detects the concentration and level of total volatile organic compounds (TVOC) in the air, as well as temperature and humidity, and can be bound with an Aqara hub to enable home automations;
Aqara Smart Wall Switch H1 EU** (£39.99-£42.99) - Aqara’s first wall switch designed for Europe, available in both With Neutral and No Neutral versions;
To celebrate the launch, Aqara now offers a limited-time discount of 10% OFF for all purchases on its Amazon UK store with the promo code: AmazonUKPR. The offering is valid through July 30, 2021.
* All prices include VAT.
** Aqara TVOC Air Quality Monitor and Wall Switch H1 EU will be available on Amazon UK in the following weeks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005229/en/
Contact information
For Media Inquiry:
Michell Li
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom